Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.
Barnett
David
D
Stevens
Andrew
A
Longson
Carole
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D007880:Legislation, Drug / Q000191:economics / Q000458:organization & administration; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab